Advertisement
Research Article

Assessing Predicted HIV-1 Replicative Capacity in a Clinical Setting

  • Roger D. Kouyos equal contributor mail,

    equal contributor Contributed equally to this work with: Roger D. Kouyos, Viktor von Wyl, Huldrych F. Günthard, Sebastian Bonhoeffer

    sebastian.bonhoeffer@env.ethz.ch (SB); rkouyos@princeton.edu (RDK)

    Affiliations: ETH Zürich, Institute of Integrative Biology, Zürich, Switzerland, Princeton University, Department of Ecology and Evolutionary Biology, Princeton, New Jersey, United States of America

    X
  • Viktor von Wyl equal contributor,

    equal contributor Contributed equally to this work with: Roger D. Kouyos, Viktor von Wyl, Huldrych F. Günthard, Sebastian Bonhoeffer

    Affiliation: Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland

    X
  • Trevor Hinkley,

    Affiliation: ETH Zürich, Institute of Integrative Biology, Zürich, Switzerland

    X
  • Christos J. Petropoulos,

    Affiliation: Monogram Biosciences, South San Francisco, California, United States of America

    X
  • Mojgan Haddad,

    Affiliation: Monogram Biosciences, South San Francisco, California, United States of America

    X
  • Jeannette M. Whitcomb,

    Affiliation: Monogram Biosciences, South San Francisco, California, United States of America

    X
  • Jürg Böni,

    Affiliation: Swiss National Center for Retroviruses, Institute of Medical Virology, University of Zurich

    X
  • Sabine Yerly,

    Affiliation: Laboratory of Virology and AIDS Center, Geneva University Hospital, Geneva, Switzerland

    X
  • Cristina Cellerai,

    Affiliation: Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland

    X
  • Thomas Klimkait,

    Affiliation: Institute of Medical Microbiology, Department Biomedicine, University of Basel, Basel, Switzerland

    X
  • Huldrych F. Günthard equal contributor,

    equal contributor Contributed equally to this work with: Roger D. Kouyos, Viktor von Wyl, Huldrych F. Günthard, Sebastian Bonhoeffer

    Affiliation: Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland

    X
  • Sebastian Bonhoeffer equal contributor mail,

    equal contributor Contributed equally to this work with: Roger D. Kouyos, Viktor von Wyl, Huldrych F. Günthard, Sebastian Bonhoeffer

    sebastian.bonhoeffer@env.ethz.ch (SB); rkouyos@princeton.edu (RDK)

    Affiliation: ETH Zürich, Institute of Integrative Biology, Zürich, Switzerland

    X
  • the Swiss HIV Cohort Study
  • Published: November 03, 2011
  • DOI: 10.1371/journal.ppat.1002321

About the Authors

Roger D. Kouyos, Trevor Hinkley, Sebastian Bonhoeffer
ETH Zürich, Institute of Integrative Biology, Zürich, Switzerland
Roger D. Kouyos
Princeton University, Department of Ecology and Evolutionary Biology, Princeton, New Jersey, United States of America
Viktor von Wyl, Huldrych F. Günthard
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
Christos J. Petropoulos, Mojgan Haddad, Jeannette M. Whitcomb
Monogram Biosciences, South San Francisco, California, United States of America
Jürg Böni
Swiss National Center for Retroviruses, Institute of Medical Virology, University of Zurich
Sabine Yerly
Laboratory of Virology and AIDS Center, Geneva University Hospital, Geneva, Switzerland
Cristina Cellerai
Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
Thomas Klimkait
Institute of Medical Microbiology, Department Biomedicine, University of Basel, Basel, Switzerland

Corresponding Authors

Competing Interests

Potential conflicts of interest: H.F.G. has been an adviser and/or consultant for GlaxoSmithKline (GSK), Abbott, Gilead, Merck Sharp & Dohme (MSD), Novartis, Boehringer Ingelheim, Roche, Tibotec, Jansen-Cilag and Bristol-Myers Squibb (BMS) and has received unrestricted research and educational grants from Roche, Abbott, BMS, GSK, Gilead, Pfizer, ViiV Healthcare, Tibotec, and MSD (all money went to institution). S.Y. has participated in advisory boards of BMS and Tibotec and has received travel grants from GSK and MSD. M.C. has received travel grants from Abbott, Boehringer Ingelheim, and Gilead. E.B. has been an advisor and/or consultant for Gilead and Abbott, has been a member of an advisory board of ViiV, Gilead, Tibotec, Pfitzer, and MSD, and has received research grants from Gilead and Abbott as well as travel grants from BMS, Gilead, ViiV, MSD, Abbott, and Tibotec. P.L.V. has been a member of an advisory board of MSD, Tibotec, Gilead, and ViiV and has received payment for lectures from Gilead, Tibotec, and GSK. All other authors report no potential conflicts.

Author Contributions

Conceived and designed the experiments: RDK VVW CJP SB HFG. Performed the experiments: MH JMW JB SY CC TK. Analyzed the data: RDK VVW TH. Contributed reagents/materials/analysis tools: TH CJP MH JMW JB SY CC TK. Wrote the paper: RDK VVW HFG SB.